scholarly journals Real-Time Automated Pathogen Identification by Enhanced Ribotyping (RAPIER) LDRD Final Report

2018 ◽  
Author(s):  
Michael S. Bartsch ◽  
Sara Bird ◽  
Steven Branda ◽  
Harrison Edwards ◽  
Harikrishnan Jayamohan ◽  
...  
2020 ◽  
Vol 154 (3) ◽  
pp. 387-393
Author(s):  
Molly E Klein ◽  
Joseph W Rudolf ◽  
Maryna Tarbunova ◽  
Tanya Jorden ◽  
Susanna R Clark ◽  
...  

Abstract Objectives We sought to make pathologists’ intraoperative consultation (IOC) results immediately available to the surgical team, other clinicians, and laboratory medicine colleagues to improve communication and decrease postanalytic errors. Methods We created an IOC report in our stand-alone laboratory information system that could be signed out prior to, and independent of, the final report, and transfer immediately to the electronic health record (EHR) as a preliminary diagnosis. We evaluated two metrics: preliminary (IOC) result review in the EHR by clinicians and postanalytic errors. Results We assessed 2,886 IOC orders from the first 22 months after implementation. Clinicians reviewed 1,956 (68%) of the IOC results while in preliminary status, including 1,399 (48%) within the first 24 hours. We evaluated 150 cases preimplementation and 300 cases postimplementation for discrepancies between the pathologist’s IOC result and the IOC result recorded by the surgeon in the operative note. Discrepancies dropped from 12 of 150 preimplementation to 6 of 150 and 7 of 150 in postimplementation years 1 and 2. One of the 25 discrepancies had a major clinical impact. Conclusions Real-time reporting of IOC results to the EHR reliably transmits results immediately to clinical teams. This strategy reduces but does not eliminate postanalytic interpretive errors by clinical teams.


2018 ◽  
Vol 9 (4) ◽  
pp. 2
Author(s):  
Paul Langley ◽  
Robert E Martin

Blockchains have the potential, if appropriately implemented and managed, of contributing to a fundamental change in the application of techniques of health technology assessment in formulary decision making. Rather than continuing to rely on claims made by manufacturers that are non-evaluable, the introduction of blockchains as adjunct to the electronic medical record, meet an unmet medical need in enabling a platform for the real time assessment of claims. Rather than focusing the case for their product on lifetime cost-per-QALY models, which have no chance of ever being validated, the blockchain platform offers a low cost opportunity for claims evaluation. Manufacturers would be required to abandon the construction of imaginary cost-per-QALY worlds to support claims for pricing and formulary trier position, in favor of claims that can be evaluated and reported back to formulary committees in a short yet meaningful time horizon. Manufacturers would present a claims assessment protocol as part of the formulary submission package. If agreed with the formulary committee, the protocol would be implemented and managed through the patient blockchain membership. Claims would be monitored and evaluated in real time with a final report to the formulary committee in a matter of months. Lifetime imaginary claims for cost-per-QALY, set alongside willingness-to-pay thresholds, would be a thing of the past. Pricing decisions and formulary placement would reflect a robust evidence base and not just extrapolations from pivotal clinical trials.   Article Type: Commentary


Lab on a Chip ◽  
2006 ◽  
Vol 6 (7) ◽  
pp. 886 ◽  
Author(s):  
Jeong-Gun Lee ◽  
Kwang Ho Cheong ◽  
Nam Huh ◽  
Suhyeon Kim ◽  
Jeong-Woo Choi ◽  
...  

2017 ◽  
Vol 196 (12) ◽  
pp. 1610-1612 ◽  
Author(s):  
Kathryn M. Pendleton ◽  
John R. Erb-Downward ◽  
Yuwei Bao ◽  
William R. Branton ◽  
Nicole R. Falkowski ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document